Amgen invests big in new science and innovation center

3 September 2025

US biotech major Amgen (Nasdaq: AMGN) yesterday revealed its plan to invest more than $600 million in a new, state-of-the-art center for science and innovation at its global headquarters in Thousand Oaks, California.

The center is designed to bring together researchers, engineers and scientists across disciplines to enhance collaboration and accelerate the discovery of next-generation therapeutics for patients with the most serious diseases. The building will feature advanced automation and digital capabilities, empowering scientists with the tools and environment needed to drive scientific excellence and advancements in biotechnology.

Amgen's investments comes alongside similar commitments from a dozen other US and foreign drugmakers, intensifying pressure from the Trump administration for pharmaceutical companies to onshore manufacturing. The White House has floated tariffs of up to 250%

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK